Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
Coherus Biosciences (CHRS) Stock Price & Analysis
1,202 Followers
CHRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.43 - $8.34
Previous Close$2.15
Volume717.05K
Average Volume (3M)3.32M
Market Cap
$236.08M
Enterprise Value$353.16M
Total Cash (Recent Filing)$117.75M
Total Debt (Recent Filing)$226.89M
Price to Earnings (P/E)-0.8
Beta1.79
Next Earnings
May 09, 2024EPS Estimate
-$0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.57
Shares Outstanding112,714,488
10 Day Avg. Volume1,679,014
30 Day Avg. Volume3,324,003
Standard Deviation0.18
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.91
Price to Sales (P/S)0.94
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.57
Enterprise Value/Gross Profit3.59
Enterprise Value/Ebitda-1.81
Forecast
1Y Price Target
$9.50Price Target Upside356.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Coherus Biosciences News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $1.43 and its highest was $8.34 in the past 12 months.
What is Coherus Biosciences’s market cap?
Currently, no data Available
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is May 09, 2024 which is in 19 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on Mar 13, 2024. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.207 by -$0.503.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -$0.25.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 113,498,410 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.207. Following the earnings report the stock price went down -5.652%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Among the largest hedge funds holding Coherus Biosciences’s share is Woodline Partners LP. It holds Coherus Biosciences’s shares valued at 2M.
---
Coherus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (356.73% Upside)
$9.50 (356.73% Upside)
Blogger Sentiment
Bullish
CHRS Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 327.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $99.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
30.94%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
---
CHRS Earnings Call
Q4 2024
0:00 / 0:00
---
CHRS Stock 12 Months Forecast
Average Price Target
$9.50
▲(356.73% Upside)
Technical Analysis
Best Analysts Covering CHRS
1 Year
1 Year Success Rate
3/19 ratings generated profit
1 Year Average Return
-27.75%
reiterated a buy rating 10 months ago
Copying Lorenzo Biasio's trades and holding each position for 1 Year would result in 15.79% of your transactions generating a profit, with an average return of -27.75% per trade.
---